The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...

In a historic medical breakthrough, Northwestern Medicine surgeons successfully split a deceased donor’s liver to save two ...

Barclay Missen had resigned himself to hospice care.Missen, a 53-year-old from Chicago, got diagnosed with stage IV ...

The biotech unveiled a new research program in alpha-1 antitrypsin deficiency, a disease that’s also a focus for rival Beam ...

When an organ is injured, our body initiates a healing process. If the injury is repeated or chronic, it can lead to an ...

Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...

Understanding liver fibrosis progression through machine learning provides valuable insights into disease mechanisms, ...

Sarepta Therapeutics Inc.'s stock tumbled 23% on Tuesday after the biotech said a patient who used its gene therapy Elevidys for the rare disease Duchenne muscular dystrophy has died of acute liver ...

A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...

A 65-year-old male presented for his annual exam. The medical assistant (MA) checking the patient in remarked that he is asymptomatic except for reporting being a little bit more fatigued than usual.

Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway.

Taxpayers are footing a £130m-a-year bill for disability benefit claims linked to alcohol and drug abuse, official statistics show.